Source 1primary paper2022Science Advances
Toolkit/self-sufficient subcutaneous push button-controlled cellular implant
self-sufficient subcutaneous push button-controlled cellular implant
Also known as: self-sufficient push-button device, subcutaneous implant
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The self-sufficient subcutaneous push button-controlled cellular implant is an implantable delivery harness powered by repeated gentle finger pressure on the overlying skin. Finger-pressure actuation deforms an embedded piezoelectric membrane, generates low-voltage electrical energy, and triggers rapid biopharmaceutical release from engineered electro-sensitive human cells.
Usefulness & Problems
Why this is useful
This system enables user-controlled, on-demand biopharmaceutical release without an external power supply, using simple manual actuation through the skin. The source literature specifically indicates that release can be fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Source:
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Problem solved
It addresses the problem of achieving rapid, controllable drug release from a subcutaneous cellular implant using a self-sufficient actuation method. The reported design converts gentle finger الضغط into electrical stimulation that activates engineered cells for biopharmaceutical output.
Source:
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
electrically triggered biopharmaceutical releasemechanical actuation by finger pressurepiezoelectric energy generationTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
The implant is subcutaneous and contains an embedded piezoelectric membrane coupled to engineered electro-sensitive human cells. Practical details such as the piezoelectric material, construct architecture, implantation procedure, and cell-engineering design are not described in the supplied evidence.
The supplied evidence is limited to a single 2022 Science Advances report and does not provide independent replication. The available text does not specify long-term implant performance, quantitative release metrics, safety, durability, or validation across multiple therapeutic payloads.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug self-sufficient-subcutaneous-push-button-controlled-cellular-implant
Here, we describe a self-sufficient subcutaneous push button-controlled cellular implant powered simply by repeated gentle finger pressure exerted on the overlying skin.
Source:
control modulationsupports
Biopharmaceutical release from the implant system is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Release is fine-tuned by varying the frequency and duration of finger-pressing stimulation.
Source:
mechanismsupports
Finger-pressure actuation of the subcutaneous implant deforms an embedded piezoelectric membrane and generates sufficient low-voltage energy to trigger rapid biopharmaceutical release from engineered electro-sensitive human cells.
Pushing the button causes transient percutaneous deformation of the implant's embedded piezoelectric membrane, which produces sufficient low-voltage energy inside a semi-permeable platinum-coated cell chamber to mediate rapid release of a biopharmaceutical from engineered electro-sensitive human cells.
Source:
therapeutic effectsupports
Finger-pressure activation of the subcutaneous implant restored normoglycemia in a mouse model of type 1 diabetes as a proof of concept.
As proof of concept, we show that finger-pressure activation of the subcutaneous implant can restore normoglycemia in a mouse model of type 1 diabetes.
Source:
Comparisons
Source-backed strengths
A key strength is autonomous operation based on repeated gentle finger pressure rather than an external electronic power source. The literature also supports rapid release and tunable output, with modulation achieved by changing the frequency and duration of pressing.
Ranked Citations